Appetite Control and Biotherapy in the Management of Autoimmune Induced Global Chronic Diseases

Abstract

Editorial Appetite control with relevance to immunometabolism has become critical to the treatment of non-alcoholic fatty liver disease (NAFLD), cardiovascular disease and diabetes [1-4]. The major defect in global chronic disease is autoimmune disease with defective adipose tissue and liver interaction involved with the release of inflammatory cytokines and adipocytokines [5] relevant to toxic immune reactions that involve the pancreas brain, heart, thyroid, kidneys and reproductive organs. Appetite control and autoimmune disease are connected with the identification of Sirtuin 1 (Sirt 1) as the anti-aging gene [1-3] involved in appetite regulation and the prevention of autoimmune disease [4].